Background: Hepatocellular carcinoma (HCC) accounted as the sixth most prevalent cancer worldwide and the third most common cancer leading to death. However unfortunately only a minority HCC patients are surgical candidates at the time of diagnosis, Transcatheter arterial chemoembolization (TACE) is one of the most commonly used intra-arterial therapies to treat unresectable HCC, Assessing early response to therapy using objective criteria is paramount for clinical care.